MODEL RELEASED. Preparation of Moroctocog alfa (trade name ReFacto), a factor VIII (FVIII) blood clotting agent for intravenous injection in a haemoph
MODEL RELEASED. Preparation of Moroctocog alfa (trade name ReFacto), a factor VIII (FVIII) blood clotting agent for intravenous injection in a haemophiliac patient. The concentrated preparation is reconstituted before injection. Haemophilia is a hereditary disorder in which the blood clots very slowly, due to a deficiency in one of the blood coagulation factors. FVIII, also known as anti-haemophilic factor (AHF), is an essential blood clotting agent in humans.
Size: 5173px × 3449px
Photo credit: © DR P. MARAZZI/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: 8, 500, agent, ahf, alfa, anti-haemophilic, antihaemophilic, biotechnology, blood, body, bottle, chinese, cho, clotting, coagulation, concentrate, drug, drugs, engineered, engineering, factor, fviii, genetic, genetically, gm, gmo, haematological, haematology, haemophilia, haemophiliac, hamster, hands, healthcare, hematology, hemophilia, hemophiliac, human, injection, intravenous, iu, iv, medical, medication, medicine, modification, moroctocog, ovary, patient, people, person, pharmaceutical, pharmaceuticals, pharmaceutics, pharmacological, pharmacology, phial, powder, preparing, product, recombinant, reconstitution, refacto, syringe, therapy, treatment, vial, viii
